We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Healthcare ETF (JHMH) Hits New 52-Week High
For investors seeking momentum, the John Hancock Multifactor Healthcare ETF is probably on radar. The fund just hit a 52 week-high, and shares of JHMH are up roughly 22% from their 52-week low price of $29.91/share.
But could more gains be in store for this ETF? Let’s take a quick look at the fund and the near term outlook to get a better idea on where it might be headed:
JHMH in Focus
The fundfocuses on the healthcare segment of the market and comprises 106 holdings. Johnson & Johnson (JNJ - Free Report) occupies the top weight with 6.55% weight. It has a large-cap bias (80%) (see: all the Health Care ETFs).
Why the move?
Healthcare stocks are hot with Democrats taking the house in midterm elections as this is supposed to reduce the risk of Republicans cancelling or weakening Obamacare. Approval of Medicaid expansion referendums in Idaho, Nebraska and Utah were taken in positive light as it would allow thousands of poor Americans to gain access to healthcare coverage.
More Gains Ahead?
Currently, JHMH has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook, so there is definitely still some promise for those who want to try to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>